Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,001–6,100 of 15,747
Cantoni, D. M., Siracusano, G., Neto, M. M., Pastori, C., Fantoni, T., Lytras, S., Genova, C. D., Hughes, J., on behalf of the Ambulatorio Medico San Luca Villanuova Group, Lopalco, L., et al. (2022) · Vaccines · doi:10.3390/vaccines11010058 · Cited by 14
Lack of immune response after mRNA vaccination to SARS‐CoV‐2 in a solid organ transplant patient
Rusk, D. S., Strachan, C. C., & Hunter, B. R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27044 · Cited by 13
“Phase 3 trials of both mRNA‐1273 and BNT162b2 did include a small number of human immunodefeciency virus (HIV)‐ positive patients, but the results were not stratified by HIV status, and the number of enrolled HIV‐positive patients was quite small.(1,2) A small study of 187 transplant patients showed no serious adverse…”
BackgroundResultLafarge, A., Mabrouki, A., Yvin, É., Bredin, S., Binois, Y., Clère-Jehl, R., & Azoulay, É. (2021) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000907 · Cited by 13
Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.29.573647 · Cited by 13
Milito, C., Soccodato, V., Collalti, G., et al. (2021) · Vaccines · doi:10.3390/vaccines9060626 · Cited by 14
Work Absence Following COVID-19 Vaccination in a Cohort of Healthcare Personnel
Breeher, L. E., Wolf, M. E., Geyer, H. L., Brinker, T., Tommaso, C., Kohlnhofer, S., Hainy, C., & Swift, M. D. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002376 · Cited by 14
Ocular motility disorders following coronavirus disease-19 vaccination
Park, K., Jeon, H., Choi, D. G., Jung, J. H., Shin, H.-J., Lee, B. J., Moon, Y., Lee, D. C., Lee, D. C., Cho, S. Y., et al. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05888-z · Cited by 15
Interstitial pneumonitis after COVID-19 vaccination: A report of three cases
Shimizu, T., Watanabe, S., Yoneda, T., et al. (2021) · Allergology International · doi:10.1016/j.alit.2021.10.003 · Cited by 14
Bondue, T., Berlingerio, S. P., Siegerist, F., Garví, E. S., Schindler, M., Baelde, H. J., Cairoli, S., Goffredo, B. M., Arcolino, F. O., Dieker, J. W. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47085-w · Cited by 16
“Messenger RNA (mRNA-) based approaches have gained considerable attention during the SARS-CoV2 pandemic following the extensive use of mRNA vaccines 9–11 .”
BackgroundIto, Y., Honda, A., & Kurokawa, M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.03.012 · Cited by 15
The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels
Noureldine, H. A., Maamari, J., Helou, M. O. E., Chedid, G., Farra, A., Husni, R., & Mokhbat, J. (2022) · Immunologic Research · doi:10.1007/s12026-022-09309-5 · Cited by 14
“Although initial trials have confirmed the safety of the vaccine [5], the risk of emerging adverse events cannot be discounted, especially given the relatively short surveillance period prior to FDA emergency use authorization.”
BackgroundCurrent advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review
Sanyaolu, A. O., Okorie, C., Marinkovic, A., Prakash, S., Williams, M., Haider, N., Mangat, J., Hosein, Z., Balendra, V., Abbasi, A. F., et al. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221097559 · Cited by 16
Ethical reflections on Covid-19 vaccines
Raus, K., Mortier, E. P., & Eeckloo, K. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1925027 · Cited by 14
Ram, R., Freund, T., Halperin, T., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.02.012 · Cited by 14
Chen, Q., Du, P., Han, Y., Ma, X., Zhang, R., Rong, X., Zhao, X., Ma, R., Yang, H., Zheng, A., et al. (2023) · Biosafety and Health · doi:10.1016/j.bsheal.2023.02.002 · Cited by 13
Nanotechnology and COVID-19: quo vadis?
Tavares, J. L., Cavalcanti, I. D. L., Santos-Magalhães, N. S., & Nogueira, M. C. D. B. L. (2022) · Journal of Nanoparticle Research · doi:10.1007/s11051-022-05452-0 · Cited by 17
“The difference between the two is related to the genetic material: Moderna (mRNA-1273) uses stabilized mRNA from viral spike protein, while BNT162b2 from Pfizer/BioNTech uses nucleoside-modified RNA (modRNA) from SARS-CoV-2 (Dai and Gao 2021; Polack et al. 2020; Walsh et al. 2020a, 2020b; Zhang et al. 2020b).”
BackgroundJavanbakht, M., Khan, L., Mustanski, B. S., SHOPTAW, S. J., Baum, M. K., Mehta, S. H., Kirk, G. D., Lai, S., Moore, R. D., Milloy, M., et al. (2023) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102300 · Cited by 14
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
Brinkkemper, M., Brouwer, P. J. M., Maisonnasse, P., Grobben, M., Caniels, T. G., Poniman, M., Burger, J. A., Bontjer, I., Oomen, M., Bouhuijs, J. H., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00411-7 · Cited by 18
COVID-19 primary series and booster vaccination and potential for immune imprintingPreprint
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.10.31.22281756 · Cited by 14
Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study
Lee, D. S., Kim, J. W., Lee, K. L., Jung, Y. J., & Kang, H. W. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.05.044 · Cited by 14
“These vaccines are effective in preventing COVID-19 infection and are generally safe to use with a low incidence of adverse events (AEs) [4-9,10].”
Alimohammadi, R., Porgoo, M., Eftekhary, M., Kiaie, S. H., Dezfouli, E. A., Dehghani, M., Nasrollahi, K., Malekshahabi, T., Heidari, M., Pouya, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00528-3 · Cited by 15
Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex
Du, P., Huang, L., Fang, Y., Zhao, F., Li, Q., Ma, X., Li, R., Chen, Q., Shen, H., Wang, Q., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012116 · Cited by 15
Why Molnupiravir Fails in Hospitalized Patients
Brown, A. N., Lang, Y., Zhou, J., Franco, E. J., Hanrahan, K. C., Bulitta, J. B., & Drusano, G. L. (2022) · mBio · doi:10.1128/mbio.02916-22 · Cited by 17
Tougeron, D., Hentzien, M., Seitz‐Polski, B., Bani‐Sadr, F., Bourhis, J., Ducreux, M. P., Gaujoux, S., Gorphe, P., Guiu, B., Hoang‐Xuan, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.030 · Cited by 15
Epidemiological aspects of headache after different types of COVID ‐19 vaccines: An online survey
Magdy, R., Khedr, D. M., Yacoub, O., Attia, A., Abdelrahman, M. A., & Mekkawy, D. (2022) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14374 · Cited by 14
Nguyen, S., Bastien, E., Chrétien, B., Sassier, M., Defer, G. L., Nehme, A., Lelong‐Boulouard, V., Alexandre, J., Fédrizzi, S., & Morice, P. (2022) · Annals of Neurology · doi:10.1002/ana.26494 · Cited by 15
“S (Janssen/Johnson & Johnson; n = 21,895 in the vaccine group),(30) mRNA-1273 (Moderna; n = 15,181 in the vaccine group), 31 and BNT162b2 (Pfizer/BioNTech; n = 18,860 in the vaccine group).(32) Although NVXCoV2373 (Novavax) was marketed more than 1 year after the other SARS-CoV-2 vaccines, only 500 VigiBase reports we…”
BackgroundVoices of Undergraduate Students With Disabilities During the COVID-19 Pandemic: A Pilot Study
Kourea, L., Christodoulidou, P., & Fella, A. (2021) · European Journal of Psychology Open · doi:10.1024/2673-8627/a000011 · Cited by 25
Leong, D. P., Banerjee, A., & Yusuf, S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.04.012 · Cited by 16
Peterhoff, D., Einhauser, S., Beileke, S., Niller, H.-H., Günther, F., Schachtner, M., Asbach, B., Steininger, P. A., Tenbusch, M., Peter, A. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10020324 · Cited by 14
Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis
Ionita, C., Marcelli, D., Nita, C., Anton, C., Berca, S., Vacar, S., Schiller, O., Gheorghiu, C., & Barth, C. (2022) · Journal of Nephrology · doi:10.1007/s40620-021-01195-8 · Cited by 12
“In Romania, both the mRNA Covid-19 vaccines BNT162b2 [8] and mRNA-1273 [9] were available for patients on hemodialysis.”
BackgroundMethodInfluentialKhor, S., Omae, Y., Takeuchi, J. S., Fukunaga, A., Yamamoto, S., Tanaka, A., Matsuda, K., Kimura, M., Maeda, K., Ueda, G., et al. (2022) · Vaccines · doi:10.3390/vaccines10040563 · Cited by 15
“BNT162b2 was designed to present the entire spike glycoprotein of SARS-CoV-2 as a target to elicit neutralizing antibodies and so block viral entry through the angiotensin-converting enzyme 2 (ACE2) cellular receptor, particularly the viral sequences recognizing the receptor-binding domain [28].”
BackgroundMethodMubarak, A., Almutairi, S. M., Al-Dhabbah, A. D., Aldabas, S. Y., Bhat, R., Alqoufail, M. M., Abdel-Maksoud, M. A., Almanaa, T. N., Farrag, M. A., & Alturaiki, W. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s369769 · Cited by 16
“The FDA approved the emergency use of SARS-CoV-2 mRNA vaccines with a two-dose schedule in December 2020; BNT162b2/Pfizer for instance.(10,11) While phase 3 trials for both vaccines showed excellent effectiveness in preventing symptomatic SARS-CoV-2 infections after the second dose, new studies suggest that a single d…”
MethodXu, R., Lu, T., Zhao, J., Wang, J., Peng, B., & Zhang, L.-Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815596 · Cited by 17
“The clinical safety of mRNA vaccines was indeed confirmed after their vast clinical application in COVID-19 prevention (Polack et al., 2020).”
BackgroundBudhadev, D., Hooper, J., Rocha, C., Nehlmeier, I., Kempf, A., Hoffmann, M., Krüger, N., Zhou, D.-J., Pöhlmann, S., & Guo, Y. (2023) · JACS Au · doi:10.1021/jacsau.3c00163 · Cited by 11
Seban, R., Richard, C., Nascimento-Leite, C., Ghidaglia, J., Provost, C., Gonin, J., Tourneau, C. L., Romano, E., Deleval, N., & Champion, L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263082 · Cited by 14
“263082 A billion doses of the currently authorized and recommended messenger RNA (mRNA) (1,2) or viral vector vaccine (3) against coronavirus disease 2019 (COVID-19) have been administered worldwide.”
BackgroundPettini, E., Medaglini, D., & Ciabattini, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058748 · Cited by 15
“The first data on Moderna and Pfizer mRNA COVID-19 vaccines showed a promising efficacy around 95% (9, 10).”
BackgroundFrequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination
Horvat, J. V., Sevilimedu, V., Becker, A. S., Pérez-Johnston, R., Yeh, R., & Feigin, K. (2022) · European Radiology · doi:10.1007/s00330-022-08655-0 · Cited by 14
Transient Lymphocytic Colitis After SARS-CoV2 mRNA Vaccine
Chey, S. W., Westerhoff, M. A., & Chey, W. D. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001673 · Cited by 13
Yakou, F., Saburi, M., Hirose, A., Akaoka, H., Hirota, Y., Kobayashi, T., Awane, N., Asahi, N., Amagawa, T., Ozawa, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.840580 · Cited by 15
“On the other hand, the COVID-19 vaccine is reportedly associated with nausea and vomiting as adverse effects (3, 4).”
BackgroundClinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Levine, S., François, F., Iturrate, E., Wang, G., Dittmann, M., Lighter, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104141 · Cited by 15
A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response
Kim, W., Song, E. S., Lee, S. H., Yang, S. H., Cho, J., & Kim, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-58315-0 · Cited by 17
Barda, N., Canetti, M., Gilboa, M., Asraf, K., Indenboim, V., Weiss-Ottolenghi, Y., Amit, S., Zubli, D., Doolman, R., Mendelson, E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac886 · Cited by 16
Wang, H., & Cheng, Y. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70002 · Cited by 19
Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report
Šín, R., & Struncova, D. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i24.7218 · Cited by 14
Kaabi, N. A., Oulhaj, A., Hosani, F. I. A., Mazrouei, S. K. A., Najim, O., Hussein, S. E., Abdalla, J. S., Fasihuddin, M. S., Hassan, A., ElGhazali, G. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04244-1 · Cited by 14
Tani, N., Ikematsu, H., Goto, T., Gondo, K., Inoue, T., Yanagihara, Y., Kurata, Y., Oishi, R., Minami, J., Onozawa, K., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac493 · Cited by 15
“Around 15% of vaccinees had fever after the second or third dose of an mRNA COVID-19 vaccine [1, 9, 10], while only 1%–2% did so after influenza or pneumococcal vaccination [11, 12].”
BackgroundDelayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19
Heldman, M. R., Kates, O. S., Safa, K., Kotton, C. N., Multani, A., Georgia, S. J., Steinbrink, J. M., Alexander, B. D., Blumberg, E. A., Haydel, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac159 · Cited by 16
“This study took place prior to the advent of SARS-CoV-2 vaccines, which dramatically reduce mortality from COVID-19 in SOT recipients and the general population [34-37].”
MethodFerreira, F. D. Q. T., Araújo, D. C., de Albuquerque, L. M., Bianchini, P. M., de Holanda, E. C., & Pugliesi, A. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2093756 · Cited by 13
Nakagawa, N., Maruyama, S., Kashihara, N., Narita, I., & Isaka, Y. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02231-y · Cited by 15
A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization
Wiest, N. E., Johns, G. S., & Edwards, E. (2021) · Vaccines · doi:10.3390/vaccines9080903 · Cited by 14
“In fact, VTE was not reported as an adverse event during Phase III studies of the Pfizer-BioNTech and Moderna SARS-CoV-2 mRNA vaccines, illustrating the rarity of these events [23,24].”
BackgroundBongiovanni, M., Liuzzi, G., Schiavon, L., Gianturco, L., & Giuliani, G. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104962 · Cited by 14
Riccò, M., Corrado, S., Palmieri, S., & Marchesi, F. (2023) · Children · doi:10.3390/children10071169 · Cited by 19
Syrigos, N. K., Κόλλιας, Α., Grapsa, D., Fyta, E., Kyriakoulis, K. G., Vathiotis, I. A., Kotteas, E. A., & Syrigou, E. I. (2022) · Vaccines · doi:10.3390/vaccines10050745 · Cited by 14
Luangdilok, S., Wanchaijiraboon, P., Pakvisal, N., Susiriwatananont, T., Zungsontiporn, N., Sriuranpong, V., Sainamthip, P., Suntronwong, N., Vichaiwattana, P., Wanlapakorn, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10101613 · Cited by 13
Li, D., Debbas, P., Mujukian, A., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac174 · Cited by 14
Why use methods that require proportional hazards?
Stensrud, M. J., & Hernán, M. Á. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae361 · Cited by 16
Cheng, C., Jiang, W., Fan, B., Cheng, Y., Hsu, Y., Wu, H.-Y., Chang, H., & Tsou, H. (2023) · BMC Public Health · doi:10.1186/s12889-023-16419-8 · Cited by 17
Kanji, J. N., Bailey, A., Fenton, J., Ling, S. H., Rivera, R., Plitt, S. S., Sligl, W., Taylor, S. C., Turnbull, L., Tipples, G. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.022 · Cited by 13
Keresztes, G., Baer, M., Alfenito, M. R., Verwoerd, T. C., Kovalchuk, A., Wiebe, M. G., Andersen, T. K., Saloheimo, M., Tchelet, R., Kensinger, R. D., et al. (2022) · Vaccines · doi:10.3390/vaccines10020148 · Cited by 15
Dual targeted lipid nanoparticles for enhanced DNA delivery and transfection of breast cancer cells
Lotter, C., Stierli, M. A., Puligilla, R. D., & Huwyler, J. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114674 · Cited by 16
Amodio, E., Vella, G., Restivo, V., Casuccio, A., Vitale, F. M., & On Behalf Of The Covid-Surveillance Working Group Of The University Of Palermo (2022) · Vaccines · doi:10.3390/vaccines10030426 · Cited by 14
Tan, D. H. S., Chan, A. K., Jüni, P., TOMLINSON, G. A., Daneman, N., Walmsley, S. L., Muller, M. P., Fowler, R. A., Murthy, S., Press, N., et al. (2021) · Trials · doi:10.1186/s13063-021-05134-7 · Cited by 15
Multiple Evanescent White Dot Syndrome Following COVID-19 mRNA Vaccination
Gargouri, M. A., Yousfi, N., Toutain, J., Farès, S., Lejoyeux, R., Gabison, E. E., Cochereau, I., Titah, C., & Azar, G. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2127782 · Cited by 14
Fernández‐Lázaro, D., Fernandez-Lazaro, C. I., Mielgo‐Ayuso, J., Adams, D. P., García, J. L., Gonzalez-Bernal, J. J., & González‐Gross, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698672 · Cited by 17
“Subjects who received the full, two-dose vaccine regime showed an approximately 95% efficacy rate after a median follow-period up of 2 months (119).”
BackgroundPfeiffer, P., Nilsson, J. R., Gallud, A., Baladi, T., Le, H., Bood, M., Lemurell, M., Dahlén, A., Grøtli, M., Esbjörner, E. K., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae722 · Cited by 17
Petrie, J. G., King, J. P., McClure, D. L., Rolfes, M. A. R., Meece, J. K., Pattinson, D., Neumann, G., Kawaoka, Y., Belongia, E. A., & McLean, H. Q. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13104 · Cited by 16
“efficacy of a two-dose series to be >90% in preventing symptomatic infection.(1,2) Post-authorization observational studies continued to estimate high vaccine effectiveness (VE) against symptomatic infec-”
BackgroundNanotechnology of inhalable vaccines for enhancing mucosal immunity
Li, Q., Sun, Y., Gao, N., Ling, G., & Zhang, P. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01431-7 · Cited by 16
“Vaccines are usually administrated by needle-based injection and can induce robust systemic immune responses [2, 3].”
Tan, C. S., Collier, A.-R. Y., Liu, J., Yu, J., Chandrashekar, A., McMahan, K., Wan, H., He, X., Jacob-Dolan, C., Sellers, D., et al. (2021) · medRxiv · doi:10.1101/2021.12.02.21267198 · Cited by 14
“S (booster) N=41 BNT162b2 (2 dose) BNT162b2 (booster) N=24 Age (years), median (range) 36 (23-84) 34 (23-69) Sex at birth, female 32 (78) 21 (88) Race White 30 (73) 20 (83) Asian 5 (12) 2 (8) Black 3 (7) 1 (4) More than one race Unknown/Other* 2 (5) 1 (2) 1 (4) 0 Ethnicity Hispanic or Latino 2 (5) 2 (8) Non-Hispanic O…”
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Liang, L.-L., Kao, C., Ho, H. J., & Wu, C. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05021 · Cited by 14
Kanokudom, S., Assawakosri, S., Suntronwong, N., Chansaenroj, J., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Duangchinda, T., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.033 · Cited by 13
“, New York, NY) contains 15 lg (reduced) or 30 lg (standard) of mRNA encoding SARSCoV-2 spike (S) protein [9].”
Bednarski, E., Estrada, P. M. D. R., DaSilva, J., Boukadida, C., Zhang, F., Luna-Villalobos, Y. A., Rodríguez-Rangel, X., Pitén-Isidro, E., Luna-García, E., Díaz-Rivera, D., et al. (2022) · mBio · doi:10.1128/mbio.00840-22 · Cited by 15
Teh, H. S., Woon, Y. L., Leong, C. T., Hing, N. Y. L., Mien, T. Y. S., Roope, L. S. J., Clarke, P., Lim, L., & Buckell, J. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100534 · Cited by 21
Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction
Marabotti, C. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2067531 · Cited by 13
“very short duration of the study [3] (median value 2 months).”
BackgroundInfluentialMiteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 20
Germany’s fourth COVID-19 wave was mainly driven by the unvaccinated
Maier, B. F., Wiedermann, M., Burdinski, A., Klamser, P., Jenny, M. A., Betsch, C., & Brockmann, D. (2022) · Communications Medicine · doi:10.1038/s43856-022-00176-7 · Cited by 19
Łysek-Gładysińska, M., Starz, M., Borowiec-Sęk, A., Sufin, I., Wieczorek, A., Chrapek, M., Zarębska‐Michaluk, D., Sufin, P., Głuszek, S., & Adamus-Białek, W. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s394760 · Cited by 17
Bayesian Strategies in Rare Diseases
Garczarek, U., Muehlemann, N., Richard, F., Yajnik, P., & Russek‐Cohen, E. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00485-y · Cited by 19
Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adultsPreprint
Demonbreun, A. R., Sancilio, A., Vaught, L. A., Reiser, N. L., Pesce, L. L., McNally, E. M., & McDade, T. W. (2021) · medRxiv · doi:10.1101/2021.11.19.21266555 · Cited by 16
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
Roederer, A. L., Cao, Y., Denis, K. S., Sheehan, M. L., Li, C. J., Lam, E. C., Gregory, D. J., Poznansky, M. C., Iafrate, A. J., Canaday, D. H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101850 · Cited by 26
“Over the course of the pandemic, 164 individual mutations in viral spike have arisen across variants of concern/interest up to JN.1, including several that occurred at the same position in the WT spike protein numbering (Figure 1D).”
Tvito, A., Ronson, A., Ghosheh, R., et al. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.396 · Cited by 14
“The BNT162b2 vaccine (BioNTech, Pfizer vaccine), tested in 43,548 participants, was reported to provide 95% protection against Covid-19 [1].”
Rheumatology and COVID-19 at 1 year: facing the unknowns
Calabrese, L. H., & Winthrop, K. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-219957 · Cited by 15
Antibody response of smokers to the COVID-19 vaccination: Evaluation based on cigarette dependence
Mori, Y., Tanaka, M., Kozai, H., Hotta, K., Aoyama, Y., Shigeno, Y., Aoike, M., Kawamura, H., Tsurudome, M., & Ito, M. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01022 · Cited by 18
“In response to this challenging situation, the emergency use of vaccines BNT162b2/Pfizer and mRNA-1273/Moderna was approved by the US Food and Drug Administration in December 2020 as a prophylactic strategy against novel coronavirus disease 2019 (COVID-19) (2,3).”
BackgroundTalmy, T., Cohen, B., Nitzan, I., & Michael, Y. B. (2021) · Journal of Community Health · doi:10.1007/s10900-021-01002-2 · Cited by 14
Validating Optimal COVID-19 Vaccine Distribution Models
Emu, M., Chandrasekaran, D., Mago, V., et al. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-77961-0_30 · Cited by 14
Factors associated with stroke after COVID-19 vaccination: a statewide analysis
Nahab, F. B., Bayakly, R. A., Sexton, M. E., Lemuel-Clarke, M., Henríquez, L., Rangaraju, S., & Ido, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1199745 · Cited by 17
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple modelPreprint
Gog, J. R., Hill, E. M., Danon, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.14.21253544 · Cited by 14
Vandeputte, J., Damme, P. V., Neyts, J. H., Audonnet, J.-C., Baay, M. F. D., & Neels, P. (2021) · Biologicals · doi:10.1016/j.biologicals.2021.08.001 · Cited by 14
Coronavirus disease 2019 (COVID-19) vaccination uptake among healthcare workers
Gilboa, M., Tal, I., Levin, E. G., Segal, S., Belkin, A., Zilberman‐Daniels, T., Biber, A., Rubin, C., Rahav, G., & Regev‐Yochay, G. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.421 · Cited by 14
“The BNT162b2 mRNA Covid-19 vaccine is a lipid nanoparticle-formulated nucleoside modified RNA vaccine that encodes a full length spike protein.[2] A two dose regimen of this vaccine confers 95% protection against COVID-19 in clinical trials and this vaccine was authorized by the FDA on December 2020 for emergency use.”
BackgroundTargeting Viral Surface Proteins through Structure-Based Design
Narkhede, Y. B., Gonzalez, K. J., & Strauch, E. (2021) · Viruses · doi:10.3390/v13071320 · Cited by 16
“vaccines [36,39,41,101], virus-like particles [102], gene-based vectors [42], and nucleic acidbased vaccines [29,30].”
BackgroundCentral diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine?
Ishay, A., & Shacham, E. C. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01296-4 · Cited by 14
Explaining higher Covid-19 vaccination among some US primary care professionals
Huang, Q. E., Gilkey, M. B., Thompson, P., Grabert, B. K., Dailey, S. A., & Brewer, N. T. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.114935 · Cited by 16
“Clinical trials and post-licensure surveillance have established that several Covid-19 vaccines effectively prevent serious health problems and death from the disease (Baden et al., 2021; Polack et al., 2020).”
SARS-CoV-2 Vaccines and the Skin
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2021.07.028 · Cited by 15
Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
Cocomazzi, G., Piazzolla, V., Squillante, M. M., Antinucci, S., Giambra, V., Giuliani, F., Maiorana, A., Serra, N., & Mangia, A. (2021) · Vaccines · doi:10.3390/vaccines9080913 · Cited by 14
“Available data regarding vaccine efficacy are derived by phase III studies on the approved vaccines with established schedules for BNT162b2 mRNA day 1 and day 21 vaccine administration, and by real-world Israeli experience [4,5].”
BackgroundMethodBachelet, T., Bourdenx, J.-P., Martinez, C., Mucha, S., Martin-Dupont, P., Perier, V., & Pommereau, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257646 · Cited by 15
“Several vaccines have been approved for SARS-CoV-2 infection, in particular, new generation lipid nanoparticle delivery of antigen encoding mRNA vaccines BNT162b2 (Pfizer-BioNTech1) [8] and mRNA-1273 (Moderna1) [9].”
BackgroundTanguay, M., Boutin, M., Laumaea, A., Salaciak, M., Mendoza, A. Y. A., Cassis, C., Ajjamada, L., Assouline, S. E., Patenaude, F., Webster‐Clark, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.040 · Cited by 13
“This RNA virus uses the receptor binding domain (RBD) of its Spike glycoprotein to enter host cells, which is the target of neutralizing antibodies acquired from natural infection [2,3] and vaccines [4,5].”
BackgroundJose, S., Dhandapani, M., Cyriac, M., & Joseph, J. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2.1952 · Cited by 14
A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study
Zeitoun, A., Hallit, S. R., Chehade, S., Ibrahim, A., Helali, M., Allam, C., & Karam, R. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-023-00528-1 · Cited by 16
“assessing the safety of PZ mRNA COVID-19 vaccine revealed that fatigue and headache were the most common AEFIs reported after the second dose [47].”
BackgroundResult
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.